19109-69-4

Usage

Physical state

Colorless to pale yellow liquid

Odor

Fruity

Uses

a. Fragrance ingredient in perfumes and personal care products
b. Intermediate in the synthesis of organic compounds (pharmaceuticals, polymers, and dyes)

Toxicity

Relatively low

Safety precautions

Handle with care and proper safety measures to avoid skin and eye irritation

Upstream product

• 67-56-1 methanol 
• 7500-53-0 1,2-Phenylenediacetic acid 
• 201230-82-2 carbon monoxide 
• 91-13-4 α,α'-dibromo-o-xylene 
• 95-47-6 o-xylene 

Downstream Products

• 104620-34-0 methyl 2-oxo-2,3-dihydro-1H-indane-1-carboxylate 
• 936479-62-8 2-(2-oxoethyl)phenylmalonic acid 
• 936479-57-1 benzyl 2-(2-hydroxyethyl)phenylacetate 
• 936479-58-2 benzyl 2-(2-methoxymethoxyethyl)phenylacetate 
• 936479-61-7 dibenzyl 2-(2-oxoethyl)phenylmalonate 
• 936479-60-6 dibenzyl 2-(2-hydroxyethyl)phenylmalonate 
• 936479-59-3 dibenzyl 2-(2-methoxymethoxyethyl)phenylmalonate 
• 136863-22-4 <2-(2-Hydroxyethyl)phenyl>essigsaeure 
• 17378-99-3 2,2’-(1,2-phenylene)diethanol 
• 150008-19-8 1,2-bis(2-bromo-2,2-dideuterioethyl)benzene 
• 63969-85-7 <2-(2-Hydroxyethyl)phenyl>essigsaeure-methylester 
• 150008-22-3 1,2-bis(2,2-dideuterio-2-hydroxyethyl)benzene 
• 72686-08-9 <2-(Methoxycarbonylmethyl)phenyl>essigsaeure 

Relevant academic research and scientific papers

PHENYLENE OXO-DIESTER PLASTICIZERS AND METHODS OF MAKING

A process for making non-phthalate, 1,2-phenylene oxo-diester plasticizers for polymer compositions, by selectively hydrogenating naphthalene to form a partially hydrogenated naphthalene, oxygenating said partially hydrogenated naphthalene to form phenylene diacids, and esterifying said phenylene diacids with oxo-alcohols to form 1,2-phenylene oxo-diesters. Also a process for making phenylene oxo-diester plasticizers by selectively brominating xylenes to form bisbromomethylbenzene, catalytic carboalkoxylation of the bromo-compound to form phenylene diacetate, followed by transesterification to form the phenylene oxo-diester.

The aldol type reaction catalyzed by arylmalonate decarboxylase - A decarboxylase can catalyze an entirely different reaction, aldol reaction

The catalytic promiscuity of AMDase was demonstrated using a well-designed substrate based on the consideration of the reaction mechanism. As the reaction catalyzed by AMDase is supposed to proceed via an enolate intermediate, we expected that the enzyme

PALLADACYLES, THEIR PREPARATION AND CATALYTIC PROCESSES INVOLVING THEIR USE AS CATALYST, ESPECIALLY CATALYTIC CARBONYLATION PROCESSES

The present invention relates to palladium compounds and their use as catalysts for improved catalytic processes. Specifically there is disclosed an improved catalytic carbonylation process and improved carbonylation catalysts. Catalysts in dimer form are also disclosed, as is their catalytic activity and methods of making the compounds.

2-aminoindane analogs

The present invention relates to therapeutically active 2-aminoindane analogs of formula (I): Also provided is a method of preparing compounds of formula (I), and pharmaceutical compositions comprising the compounds. The novel compounds act as modulators of metabotropic glutamate receptors and, as such, are useful in treating diseases of the central nervous system related to the metabotropic glutamate receptor system.

Tetrahydrobenzazepines and their use

The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, R1 and R2 have the meaninigs indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical compositon that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond benefically to dopamine D3 receptor antagonists or dopamine D3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

Manufacture of arylacetic acids and their esters

Arylacetic acids and their esters, of the formula Ar(CH2 -COOR)n (where Ar=aryl, R is H or a hydrocarbon radical, and n is 1 or 2) are manufactured by carbonylation of halomethylaryl compounds Ar(CH2 C)n (where X is Cl, Br or I) with carbon monoxide and a catalyst m+ ?Fe(O)3 NO!- (where M is an alkali metal, ammonium or one equivalent of an alkaline earth metal) in the presence of stoichiometric amounts of an inorganic base or of an alcoholate of an alcohol ROH.